Management & Regulatory

How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?
Management & Regulatory How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?

Additive manufacturing, commonly known as 3D printing, has emerged as a revolutionary technology within the biopharmaceutical industry, offering considerable benefits. One of the most compelling advantages of additive manufacturing is its potential to optimize cleanroom space through the

Is PureTech's Hub-and-Spoke Model Misunderstood by Investors?
Management & Regulatory Is PureTech's Hub-and-Spoke Model Misunderstood by Investors?

PureTech Health, a Boston-based biotechnology firm, employs an innovative "hub-and-spoke" model, centralizing resources and expertise to support various offshoot companies focused on specific therapeutic areas or drug-making technologies. This approach aims to merge the strengths of a centralized

Quantum BioPharma Sues CIBC and RBC for Alleged Spoofing and Losses
Management & Regulatory Quantum BioPharma Sues CIBC and RBC for Alleged Spoofing and Losses

Quantum BioPharma Ltd., a biotech firm specializing in neurodegenerative and metabolic disorders, has recently taken legal action against CIBC World Markets and RBC Dominion Securities. The lawsuit, filed in the United States District Court for the Southern District of New York, claims that these

CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts
Management & Regulatory CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts

In a surprising move to address ongoing financial difficulties and strategic challenges, CVS Health has made a significant leadership change by replacing CEO Karen Lynch with David Joyner, head of Caremark. This transition underscores the pressing need for CVS to stabilize its operations and refine

Are Biopharma Companies Ready for Today's Regulatory Challenges?
Management & Regulatory Are Biopharma Companies Ready for Today's Regulatory Challenges?

Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter

Pharma M&A Trends: High-Value Focus and Innovation Amid Market Fluctuations
Management & Regulatory Pharma M&A Trends: High-Value Focus and Innovation Amid Market Fluctuations

In recent years, the pharmaceutical and biotechnology sectors have experienced a dynamic landscape in mergers and acquisitions (M&A). From major multimillion-dollar deals to strategic acquisitions targeting high-demand therapeutic areas, the industry has witnessed fluctuations driven by various

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later